Larazotide acetate is the clearest test the intestinal-permeability hypothesis has yet received. It is a synthetic octapeptide that reached Phase 3 in coeliac disease — a first for the indication — and did not meet its primary endpoint. The result is instructive precisely because the preclinical rationale was strong.
01 — What larazotide acetate is
Larazotide acetate (also known as AT-1001 and, later, INN-202) is a synthetic eight-amino-acid peptide with the sequence GGVLVQPG. It is derived from a non-cytotoxic fragment of the zonula occludens toxin (Zot) produced by Vibrio cholerae, and it was developed by Alba Therapeutics and successor companies (later Innovate Biopharmaceuticals, then 9 Meters Biopharma) as an orally administered modulator of intestinal tight junctions.
Its defining property is that it acts locally in the gut lumen with minimal systemic absorption. Unlike injectable research peptides, larazotide is an oral, gut-restricted molecule — which is why it is studied as a barrier-modulating agent rather than a systemic one.
02 — The proposed mechanism
Tight junctions are the protein complexes — occludin, the claudins and the zonula occludens scaffolding proteins — that seal neighbouring epithelial cells to one another and govern what passes between them via the paracellular route. In coeliac disease, gluten-derived gliadin peptides trigger release of zonulin, which loosens these junctions and allows gliadin fragments to cross the intestinal barrier and drive an inflammatory response.
Larazotide is proposed to counteract this. Peptide Data's compound profile describes the mechanism as tight-junction stabilisation via interaction with zonula occludens-1 (ZO-1) — preventing the cytoskeletal rearrangement that zonulin triggers — rather than direct receptor-level antagonism of zonulin. The effect is described as dose-dependent and reversible. The wider literature frequently labels the compound a "zonulin antagonist"; the two descriptions overlap but are not identical, and that distinction is worth holding onto when reading secondary sources.
03 — The clinical record
Among the peptides discussed in research communities, larazotide has one of the more developed human datasets: Phase 1, several Phase 2 studies, and a Phase 3 programme.
Phase 1 (2007)
A first-in-human study in coeliac subjects established tolerability and reported reduced gut permeability in response to gliadin challenge (Paterson et al., 2007).
Phase 2b — gluten challenge
A randomised, placebo-controlled gluten-challenge study in coeliac patients reported reduced gastrointestinal symptoms and lower intestinal permeability versus placebo during gluten exposure. Notably, the clearest symptomatic signal appeared at the lower end of the dose range — an unusual, non-monotonic dose response that recurred across the programme.
Phase 2b — persistent symptoms on a gluten-free diet
A later randomised trial (Leffler et al., 2015) tested larazotide in patients with continuing symptoms despite a gluten-free diet. Symptom scores improved at some doses, but other endpoints — including serology and mucosal measures — were mixed, and the trial did not produce a clean, consistent efficacy signal.
Phase 3 (CELIAC3)
Larazotide became the first compound to enter a Phase 3 trial for coeliac disease, with patient dosing beginning in 2019. The programme did not deliver an approved product. The Phase 3 trial did not meet its primary endpoint of symptom improvement versus placebo, and development in coeliac disease was discontinued. Secondary signals and tolerability were reported as acceptable — but a miss on the primary endpoint is a miss.
04 — Why the miss matters
Larazotide is the most rigorous clinical test to date of the proposition that tightening intestinal tight junctions improves outcomes in a barrier-driven disease. That proposition has a strong mechanistic story and a deep preclinical literature — and it still failed to convert into a primary-endpoint win in a well-conducted trial. For researchers, the lesson is not that tight-junction biology is unimportant; it is that a plausible mechanism and Phase 2 symptom signals are not sufficient evidence of clinical benefit — a theme that recurs across the peptide literature.
It is also a reminder about dose–response. The recurring pattern of stronger effects at lower doses complicates both trial design and interpretation, and may have contributed to the Phase 3 outcome. In mechanistic animal work, the same zonulin pathway remains an active target — larazotide has been used experimentally to block zonulin and attenuate disease in a mouse arthritis model (Tajik et al., 2020) — but preclinical promise and clinical translation are different questions.
05 — Evidence grade
Peptide Data grades larazotide acetate Moderate. The rationale: the compound has completed multiple human trials, including Phase 3, which places it well above most research peptides — but the Phase 3 primary endpoint was not met, and it holds no marketing authorisation anywhere in the world. Moderate here reflects a real human dataset with an unresolved efficacy question, not proven benefit.
06 — UK legal status
Larazotide acetate is an investigational medicinal product. It has not received marketing authorisation from the MHRA, the EMA, the FDA or any other regulator, and it is not a licensed medicine in the UK. As a synthetic peptide, research-grade material sits in the UK "grey area": lawful to purchase and possess for bona fide laboratory research, but not licensed for human consumption or medical use. Supplying or promoting it for human use would engage the Human Medicines Regulations 2012, and the MHRA polices medicinal claims made against unlicensed products. Any use outside an approved clinical trial is investigational.
07 — Research-use-only framing
As with every compound in this reference, larazotide acetate is presented here as a subject of published research, not a product for human use. Peptide Data does not provide consumption advice or protocols for personal use; the linked compound profile records published clinical-trial designs for reference only. Anyone evaluating it as a research subject should work within institutional and regulatory frameworks.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.